
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Epidemiology Biomarkers & Prevention, Vol 6, Issue 12 987-991, Copyright © 1997 by American Association for Cancer Research
ARTICLES |
HT Lynch, SJ Lemon, B Karr, B Franklin, JF Lynch, P Watson, S Tinley, C Lerman and C Carter
Department of Preventive Medicine, Creighton University School of Medicine, Omaha, Nebraska 68178, USA.
We estimate that 5-10% of virtually all forms of cancer are due to a primary hereditary etiology. However, a hereditary cancer diagnosis is often missed because the family history of cancer is given short shrift in medical practice. Hereditary nonpolyposis colorectal cancer (HNPCC) certainly fits this estimate, although some studies suggest that a minimum of 2% with a range as high as 10% of the total colorectal cancer burden is due to HNPCC. Mutations in one of the four mismatch repair genes, i.e., hMSH2, hMLH1, hPMS1, and hPMS2, account for about 70% of HNPCC kindreds. Other germ-line mutations are likely to be identified to account for the remainder of HNPCC patients. By far the most common HNPCC mutations involve hMSH2 and hMLH1, with hPMS1 and hPMS2 accounting for only about 3% of such families. Prior to these molecular genetic discoveries, the genetic counselor could only provide the patient with an estimate of a 50% likelihood of manifesting HNPCC based on the counselee having one or more first-degree relatives manifesting syndrome cancers in their direct genetic lineage. Because DNA testing has become available in families with known mutations, we have provided pretest group education in the form of a family information service with intensive education about the natural history, genetic risk, surveillance, and options for management of HNPCC, as well as discussion of the potential for fear, anxiety, apprehension, and insurance or employer discrimination that might impact on this DNA testing. Following informed consent, these relatives were then counseled on a one-to-one basis. Using DNA-based genetic counseling involving hMSH2 or hMLH1, we have provided this service to four extended HNPCC kindreds. Details of this genetic counseling experience on these four kindreds will be discussed.
This article has been cited by other articles:
![]() |
E. S. Hong, A. Yeung, P. Funchain, M. M. Slupska, and J. H. Miller Mutants with Temperature-Sensitive Defects in the Escherichia coli Mismatch Repair System: Sensitivity to Mispairs Generated In Vivo J. Bacteriol., February 1, 2005; 187(3): 840 - 846. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Muller, T. B. Edmonston, D. A. Corao, D. G. Rose, J. P. Palazzo, H. Becker, R. D. Fry, J. Rueschoff, and R. Fishel Exclusion of Breast Cancer as an Integral Tumor of Hereditary Nonpolyposis Colorectal Cancer Cancer Res., February 1, 2002; 62(4): 1014 - 1019. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Srivastava, M. Verma, and D. E. Henson Biomarkers for Early Detection of Colon Cancer Clin. Cancer Res., May 1, 2001; 7(5): 1118 - 1126. [Abstract] [Full Text] |
||||
![]() |
H. T. Lynch and J. Lynch Lynch Syndrome: Genetics, Natural History, Genetic Counseling, and Prevention J. Clin. Oncol., November 1, 2000; 18(90001): 19s - 31. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Kopreski, F. A. Benko, D. J. Borys, A. Khan, T. J. McGarrity, and C. D. Gocke Somatic Mutation Screening: Identification of Individuals Harboring K-ras Mutations With the Use of Plasma DNA J Natl Cancer Inst, June 7, 2000; 92(11): 918 - 923. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Curia, R. Palmirotta, G. Aceto, L. Messerini, M. C. Veri, S. Crognale, R. Valanzano, F. Ficari, P. Fracasso, V. Stigliano, et al. Unbalanced Germ-Line Expression of hMLH1 and hMSH2 Alleles in Hereditary Nonpolyposis Colorectal Cancer Cancer Res., August 1, 1999; 59(15): 3570 - 3575. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. T. Lynch, M. J. Casey, T. G. Shaw, and J. F. Lynch Hereditary Factors in Gynecologic Cancer Oncologist, October 1, 1998; 3(5): 319 - 338. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |